Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
7.24
-0.47 (-6.10%)
At close: Dec 5, 2025, 4:00 PM EST
7.14
-0.10 (-1.38%)
After-hours: Dec 5, 2025, 7:37 PM EST
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$3,024,176
Market Cap
14.74M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
MBRX News
- 9 days ago - Moleculin to Participate in the Virtual Investor Closing Bell Series - GlobeNewsWire
- 9 days ago - Moleculin Announces Reverse Stock Split - GlobeNewsWire
- 22 days ago - Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented - GlobeNewsWire
- 23 days ago - Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill - GlobeNewsWire
- 5 weeks ago - Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting - GlobeNewsWire
- 5 weeks ago - Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin - GlobeNewsWire
- 6 weeks ago - Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer - GlobeNewsWire
- 2 months ago - Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin - GlobeNewsWire